S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II clinical trial will enroll patients with newly-diagnosed locally-advanced
pancreatic adenocarcinoma and adopt the Simon's two-stage optimum design. After 4 cycles of
SIROX regimen, patients will proceed to curative resection.